Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Merck's Gardasil Effective At Preventing HPV, Cervical Disease In Older Women, Study Finds
Merck"s human papillomavirus vaccine, Gardasil, was 90% effective in preventing infection with the virus and cervical disease in women ages 24 to 45, according to a study published Monday in the medical journal Lancet, Reuters reports (Fox, Reuters, 6/1). In the U.S., the vaccine currently is FDA-approved for girls and women ages nine to 26. Centers for Disease Control and Prevention guidelines recommend routine three-dose vaccination of girls ages 11 and 12 and for girls and women ages 13 to 26 who have not yet been vaccinated (CDC fact sheet, June 2008). It is designed to protect against HPV types 16 and 18, which cause about 70% of all cervical cancer cases, and HPV types 6 and 11, which cause genital warts.The new study, led by Nubia Munoz of the National Institute of Cancer in Bogota, Colombia, and funded by Merck, involved women ages 24 to 45 with no history of cervical disease or genital warts who either received the vaccine or a placebo injection. The study found that women who received the vaccine were significantly less likely to be infected with certain strains of HPV than those who received placebo shots. According to the researchers, four women out of 1,900 who received the vaccine developed HPV or cervical disease after two years, compared with 41 women out of 1,900 in the placebo group.Reuters reports that the results of the study could help Merck as it seeks approval for marketing Gardasil for use in older women. The researchers said in the study that older women might be at risk for HPV infection as "[c]hanges in sexual behavior during the past 30 years ... have led to more widespread premarital sexual intercourse and acquisition of new sexual partners around middle age." They added, "As the potential for HPV infection and disease exists in women in their third, fourth and fifth decades of life, these women could benefit from prophylactic HPV vaccination." According to Reuters, a mathematical model published in October 2005 showed that vaccinating older women could cut rates of cervical cancer in women through age 45 by half. Merck also has released data showing the effectiveness of the vaccine in preventing genital lesions in men.According to the Centers for Disease Control and Prevention, HPV is the most common sexually transmitted infection worldwide, and about 20 million U.S. residents are infected with it. The virus is the leading cause of cervical cancer, which causes about 3,870 deaths in the U.S. and 300,000 deaths globally every year, and it also can cause anal, penile, mouth and neck cancer (Reuters, 6/1).
generic viagra online
The Recommended 8 Hours Of Nightly Sleep Achieved By Less Than Half Of Older Americans
Older Americans with depressive symptoms and poor mental health tend to get seven hours of sleep per night or less, according to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
Varian Medical Systems Acquires Assets Of IKOEmed And IKOEtech; Acquisition To Add Software For Accelerating Radiotherapy Treatment Planning
Varian Medical Systems, Inc., (NYSE: VAR) announced it has acquired the assets of Houston-based IKOEmed and IKOEtech, privately-owned suppliers of software used in the planning of radiotherapy and radiosurgery treatments. The acquisition enables Varian to offer hospitals and clinics an additional software tool to automate and accelerate the most time-consuming portion of the treatment planning process. Varian is paying approximately $2.2 million plus an additional amount based on achievement of specified milestones to acquire the IKOE assets.
Oncology

Potential Medical Applications For Interactive Data Eyeglasses

For car designers, secret agents in the movies and jet fighter pilots, data eyeglasses - also called head-mounted displays, or HMDs for short - are everyday objects. They transport the wearer into virtual worlds or provide the user with data from the real environment. At present these devices can only display information. "We want to make the eyeglasses bidirectional and interactive so that new areas of application can be opened up," says Dr. Michael Scholles, business unit manager at the Fraunhofer Institute for Photonic Microsystems IPMS in Dresden. A group of scientists at IPMS is working on a device which incorporates eye tracking - users can influence the content presented by moving their eyes or fixing on certain points in the image. Without having to use any other devices to enter instructions, the wearer can display new content, scroll through the menu or shift picture elements. Scholles believes that the bidirectional data eyeglasses will yield advantages wherever people need to consult additional information but do not have their hands free to operate a keyboard or mouse. The Dresden-based researchers have integrated their system"s eye tracker and image reproduction on a CMOS chip. This makes the HMDs small, light, easy to manufacture and inexpensive. The chip measuring 19.3 by 17 millimeters is fitted on the prototype eyeglasses behind the hinge on the temple. From the temple the image on the microdisplay is projected onto the retina of the user so that it appears to be viewed from a distance of about one meter. The image has to outshine the ambient light to ensure that it can be seen clearly against changing and highly contrasting backgrounds. For this reason the research scientists use OLEDs, organic light-emitting diodes, to produce microdisplays of particularly high luminance. In industry and in the medical field, the interactive data eyeglasses could enable numerous tasks to be performed more simply, efficiently and precisely. Many scenarios are possible, including patients" vital functions, MRT and x-ray images for the operating surgeon, construction drawings for erection engineers and installation instructions for service technicians. Some users have already tried out conventional HMDs, but the results were not very impressive. In most cases they were found to be too expensive, too heavy, too bulky and not very ergonomic. "We have now overcome these hurdles," says Scholles. With his team and colleagues from other Fraunhofer institutes he is already working on the next development stage of the bidirectional eyeglasses. Michael Scholles Fraunhofer-Gesellschaft


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009